TickerFacts.

Immucell Corp (ICCC): Operating Cash Flow

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2016-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

$2.48M
Year ended 2025-12-31
$5.89M
Trailing 12 months to 2026-06-30
+13.5%
5-year compound annual growth
$2.90M2009-12-31: -$109.7K2010-12-31: -$808.6K2011-12-31: -$37.3K2012-12-31: $344.4K2013-12-31: $1.10M2014-12-31: $302.4K2015-12-31: $2.90M2016-12-31: -$222.3K2017-12-31: $1.18M2018-12-31: -$373.4K2019-12-31: $233.5K2020-12-31: $1.32M2021-12-31: $954.2K2022-12-31: -$1.54M2023-12-31: -$4.67M2024-12-31: $357.9K2025-12-31: $2.48M$2.48M
2009-12-31 Operating Cash Flow (USD) 2025-12-31
Period endedOperating Cash FlowChange YoYSource filing
2025-12-31$2.48M+591.6%2026-03-30, From 2025-01-01
2024-12-31$357.9Kn/m2026-03-30, From 2024-01-01
2023-12-31-$4.67Mn/m2025-03-28, From 2023-01-01
2022-12-31-$1.54Mn/m2024-04-01, From 2022-01-01
2021-12-31$954.2K-27.5%2023-03-29, From 2021-01-01
2020-12-31$1.32M+463.4%2022-03-30, From 2020-01-01
2019-12-31$233.5Kn/m2021-03-30, From 2019-01-01
2018-12-31-$373.4Kn/m2020-03-27, From 2018-01-01
2017-12-31$1.18Mn/m2019-03-22, From 2017-01-01
2016-12-31-$222.3Kn/c2018-03-29, From 2016-01-01
2015-12-31$2.90M+859.2%2017-03-30, From 2015-01-01
2014-12-31$302.4K-72.5%2016-03-25, From 2014-01-01
2013-12-31$1.10M+219.0%2016-03-25, From 2013-01-01
2012-12-31$344.4Kn/m2015-03-26, From 2012-01-01
2011-12-31-$37.3Kn/m2013-03-28, From 2011-01-01
2010-12-31-$808.6Kn/m2013-03-28, From 2010-01-01
2009-12-31-$109.7Kn/a2012-03-27, From 2009-01-01

Operating Cash Flow at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedOperating Cash FlowChange YoY
Immucell Corp (ICCC)2025-12-31$2.48M+591.6%
Alpha Teknova, Inc. (TKNO)2025-12-31-$8.65Mn/m
Intellia Therapeutics, Inc. (NTLA)2025-12-31-$394.74Mn/m
Aspira Women's Health Inc. (AWHL)2025-12-31-$7.03Mn/m
Anbio Biotechnology (NNNN)2025-12-31-$6.74Mn/m
Biomerica Inc (BMRA)2026-05-31-$3.42Mn/m
Insight Molecular Diagnostics Inc. (IMDX)2025-12-31-$22.18Mn/m
Volitionrx Ltd (VNRX)2025-12-31-$19.68Mn/m
Celldex Therapeutics, Inc. (CLDX)2025-12-31-$210.94Mn/m

Compare ICCC, TKNO, NTLA, AWHL side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗